养正消积胶囊联合化疗治疗转移性乳腺癌的临床疗效及安全性  

Efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in treating metastatic breast cancer

作　　者：徐志宏[1] 刘荣凤[1] 王晓翔[1] 冯莉[1] 姚铁柱[2] 刘红[3] 

机构地区：[1]河北医科大学第四医院肿瘤内科,河北石家庄050011 [2]河北医科大学第四医院心内科,河北石家庄050011 [3]河北医科大学第四医院妇瘤科,河北石家庄050011

出　　处：《山东大学学报（医学版）》2016年第5期79-83,共5页Journal of Shandong University:Health Sciences

摘　　要：目的探讨养正消积胶囊联合化疗治疗转移性乳腺癌的有效性和安全性以及对T淋巴细胞亚群的影响。方法将转移性乳腺癌79例患者按随机数字表法分为治疗组(40例)和对照组(39例);对照组给予GT化疗方案治疗,21d/周期,共6个周期;治疗组在对照组基础上口服养正消积胶囊,化疗第1天开始给予,4粒/次,3次/d,连续服用,21d/周期,共6个周期。比较两组临床疗效和不良反应;参照生活质量问卷-乳腺癌模式量表(QLQBR23)分析两组生存质量;检测两组血清T淋巴细胞亚群水平。结果治疗组总有效率为55%,明显高于对照组的28.21%(P<0.05);治疗组肝肾功能不全发生率为10%,明显低于对照组的33.33%(P<0.05);治疗后6个月,治疗组患者的体型和未来看法评分均明显高于对照组,而性功能、性乐趣、乳房症状、脱发引起的烦恼、手臂症状以及系统治疗不良反应评分均低于对照组(P<0.01);治疗后3个月,治疗组CD3+、CD4+、CD4+/CD8+水平均明显高于治疗前和对照组同期水平,而CD8+水平明显降低(P<0.01)。结论养正消积胶囊联合化疗治疗转移性乳腺癌的疗效确切,安全性高,且可明显改善患者生活质量及提高细胞免疫功能。Objective To investigate the efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in the treatment of metastatic breast cancer and its influence on T lymphocyte cell subsets. Methods A total of 79 metastatic breast cancer patients were randomly divided into the treatment group（ n = 40） and control group（ n = 39）according to digital table method. The control group was treated with GT chemotherapy,which was a total of 6 courses of treatment with q3 w. The treatment group received the same amount of chemotherapy,and Yangzheng Xiaoji capsules,4 capsules / time,3 times / day,21 days / course,for 6 courses of treatment. The clinical efficacy and adverse reactions were compared between the two groups. The survival quality of all patients was analyzed by QLQ-BR23. T sublymphocyte level was detected in both groups. Results The total efficacy rate of the treatment group was 55%,which was superior to that of the control group,28. 21%（ P 0. 05）. Incidence of liver and kidney function deficiency in the treatment group was 10%,which was lower than that of the control group,33. 33%（ P 0. 05）. Six months after treatment,scores of QLQ-BR23 in the treatment group were superior to those of the control group（ P 0. 01）. Three months after treatment,levels of CD3＋,CD4＋and CD4＋/ CD8＋of the treatment group were higher than those of the control group,while CD8＋was lower,with statistically significant difference（ P 0. 01）. Conclusion YangzhengXiaoji capsule combined with chemotherapy in treating metastatic breast cancer can increase efficacy,decrease adverse reactions,and improve quality of life and cellular immune function.

关 键 词：养正消积胶囊 转移性乳腺癌 联合化疗 T淋巴细胞亚群 

分 类 号：R737.9[医药卫生—肿瘤]